Anovulation

Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy

Retrieved on: 
Thursday, December 1, 2022
Abdominal pain, FPL, Enzyme replacement therapy, European Medicines Agency, PTC Therapeutics, Union, Pancreatitis, TG, Triglyceride, Chylomicron, Risk, Liver disease, Insulin resistance, Anovulation, Therapy, Hypertriglyceridemia, Cognition, Brain, ANVISA, Patient, HTG, Anxiety, Diet, Brazilian Health Regulatory Agency, Disease, Adipose tissue, Diabetes, Acute pancreatitis, Depression, Cirrhosis, FCS, Dyslipidemia, Hyperandrogenism, Quality of life, PTC, Lipoprotein lipase deficiency, Woman, LPL, Liver, Pharmaceutical industry, Medical imaging, Volanesorsen, Ionis

SOUTH PLAINFIELD, N.J., Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil. This is the first approval globally for Waylivra for the FPL indication. Waylivra is also approved in Brazil for the treatment of Familial Chylomicronemia Syndrome (FCS).

Key Points: 
  • SOUTH PLAINFIELD, N.J., Dec. 1, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Brazilian Health Regulatory Agency, ANVISA (Agncia Nacional de Vigilncia Sanitria), has approved Waylivra (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil.
  • This is the first approval globally for Waylivra for the FPL indication.
  • Waylivra is also approved in Brazil for the treatment of Familial Chylomicronemia Syndrome (FCS).
  • ANVISA's approval for Waylivra for FPL was based on results from the Phase 2/3 BROADEN study in patients with familial partial lipodystrophy.

India $885+ Mn Minimally Invasive Surgical Devices Markets, Analysis, Competition, Opportunity, and Forecasts, 2027F - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 26, 2022
Surgery, Health, Adoption, Pelvic pain, Disease, City, Prevalence, Growth, CAGR, Gynaecology, Patient, Hospital, Research, Anovulation, Cancer, Degenerative disease, Paniki (cutting instrument), Competition, Conditional sentence, Gastrointestinal bleeding, Menstruation, Lists of diseases, Endometriosis, Medical device, Birth control, Motor vehicle

are also supporting the growth of the Indian Minimally Invasive Surgical Devices Market in the next five years.

Key Points: 
  • are also supporting the growth of the Indian Minimally Invasive Surgical Devices Market in the next five years.
  • Minimally invasive procedures are also used in uterus removal surgeries, thereby fueling the demand for different minimally invasive surgical devices along with the market growth.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Indian Minimally Invasive Surgical Devices Market.
  • To identify key sustainable strategies adopted by the market players in the Indian Minimally Invasive Surgical Devices Market.

Award-Winning Fertility Doctor Joins Reproductive Specialists of the Carolinas

Retrieved on: 
Tuesday, October 11, 2022
REI, Reproduction, Obstetrics, Brown, Gynaecology, Reproductive medicine, Patient, IUI, Anovulation, Baylor University, University, Fibroid, Society, Healthcare disparity in Massachusetts, IVF, Pregnancy loss, RSC, Baylor College of Medicine, Fertility preservation, Medical device, Infertility, Science

CHARLOTTE, N.C., October 11, 2022 /PRNewswire-PRWeb/ -- Reproductive Specialists of the Carolinas ("RSC") is pleased to announce that Dr. Luwam Ghidei, an award-winning reproductive endocrinologist and infertility specialist, has joined the boutique fertility practice, making it possible for even more patients to receive advanced and inclusive reproductive care.

Key Points: 
  • Dr. Luwam Ghidei has joined founder Dr. Matrika Johnson and the RSC staff to further enhance the personalized fertility care for patients throughout the Carolinas.
  • CHARLOTTE, N.C., October 11, 2022 /PRNewswire-PRWeb/ -- Reproductive Specialists of the Carolinas ("RSC") is pleased to announce that Dr. Luwam Ghidei, an award-winning reproductive endocrinologist and infertility specialist, has joined the boutique fertility practice, making it possible for even more patients to receive advanced and inclusive reproductive care.
  • Reproductive Specialists of the Carolinas is located at 1918 Randolph Rd, Ste 410, Charlotte, NC 28207-1109.
  • Dr. Matrika Johnson, Reproductive Specialists of the Carolinas, +1 704.247.2209, [email protected]

Boston IVF Adds Fertility Doctor Pietro Bortoletto, MD, MSc to Stoneham, Massachusetts Fertility Center Team

Retrieved on: 
Monday, October 3, 2022
Reproductive medicine, Fertility, Fibroid, Master of Science, IUI, Reproduction, Asherman's syndrome, Weill Cornell Medicine, Brigham, Industry, Anovulation, Mullerian anomalies, Blood, CEO, Semen analysis, MD, Obstetrics, Infertility, PCOS, IVF, Embryology, Harvard Medical School, Raoul Bortoletto, Northwestern University, SIS, Male, Urology, Artificial insemination, Gynaecology, Feinberg School of Medicine, Environment, Patient, Endometriosis, Laboratory, Ovarian reserve, Beth Israel Deaconess Medical Center, Northwestern University Center for Talent Development, Media, Hysteroscopy, Mineral oil, Birth control, Medicine, Paulo

WALTHAM, Mass. , Oct. 3, 2022   /PRNewswire-PRWeb/ -- Boston IVF, one of the world's most experienced fertility treatment providers, who has assisted in over 125,000 babies born since 1986, is pleased to announce that reproductive endocrinologist Pietro Bortoletto, MD, MSc has joined its practice and physician team. Dr. Bortoletto is now accepting new patients at Boston IVF's fertility centers in Stoneham, Massachusetts and Waltham, Massachusetts.

Key Points: 
  • Dr. Bortoletto is now accepting new patients at Boston IVF's fertility centers in Stoneham, Massachusetts and Waltham, Massachusetts.
  • "Boston IVF is not just a coveted destination for individuals and couples who seek fertility care but also for fertility doctors and researchers like me," said Pietro Bortoletto, MD, MSc.
  • In addition to Dr. Bortoletto's role as a reproductive endocrinologist at Boston IVF, he also serves as the fertility network's Director of Reproductive Surgery.
  • Boston IVF's Stoneham Fertility Center offers a variety of services including consultations, IUI, blood/ultrasound monitoring, Saline Infusion Sonohysterogram (SIS), office hysteroscopy, semen analysis, and more.

France Ultrasound Infertility Diagnosis and Treatment Market Opportunity Analysis and Industry Forecasts, 2021-2022 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 23, 2022
Health, Women, Consumer, Medical Devices, Adoption, Risk, CAGR, Vaginal bleeding, Obesity, Tubing (recreation), PCOS, Diagnosis, Infertility, Ovulation, Fertility, Anovulation, Artificial insemination, Growth, Doppler ultrasonography, Lists of diseases, Uterus, Woman, Fibroid, Libraries and the LGBTQ community, Parliament, Man, IVF, Prevalence, Polyp, Male, Smoking, Endometriosis, Income, STI, Awareness, Female, Efficiency, LGBTQ, Reproduction, Medical device, Birth control

The "France Ultrasound Infertility Diagnosis and Treatment Market by Care Pathway and End User: Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "France Ultrasound Infertility Diagnosis and Treatment Market by Care Pathway and End User: Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The France ultrasound infertility diagnosis and treatment market was valued at $336.54 million in 2020, and is estimated to reach $522.36 million by 2030, growing at a CAGR of 4.4% from 2021 to 2030.
  • Ultrasound-guided infertility diagnosis is a technique in which ultrasound waves are used for determination for the cause of infertility in males as well as females.
  • However, high cost of infertility diagnosis procedures, risk associated after IVF procedure, and high cost of assisted reproductive technology hinder the market growth.

Global Infertility Treatment Market to Reach $2.1 Billion by 2026

Retrieved on: 
Tuesday, March 22, 2022
CAGR, Reproductive technology, PCOS, Infertility, Forecasting, Research, Developing country, IVF, Incidence, Thermo Fisher Scientific, Equipment, The Cooper Companies, Obesity, Players, Marketing, Diagnosis, Artificial insemination, Consumables, Female, Merck Group, Growth, Internet, Intelligence, Digital Media Consumers' Rights Act, Awareness, SAN, Anovulation, Special Program of Assisted Reproduction, GIA, COVID-19, ART, Endometriosis, Hospital, Pharmaceutical industry, Birth control, Pet, Media

SAN FRANCISCO, March 22, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Infertility Treatment - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, March 22, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Infertility Treatment - Global Market Trajectory & Analytics" .
  • Awareness about different infertility treatment procedures, increasing female infertility rate, and rising number of fertility centers will contribute the growth of female infertility treatment.
  • Amid the COVID-19 crisis, the global market for Infertility Treatment estimated at US$1.6 Billion in the year 2022, is projected to reach a revised size of US$2.1 Billion by 2026, growing at a CAGR of 6.7% over the analysis period.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer

Retrieved on: 
Monday, March 14, 2022
Biotechnology, Pharmaceutical, Health, List of life sciences, U.S. Securities and Exchange Commission, Polycystic ovary syndrome, University, Pediatric endocrinology, Twitter, Degenerative disease, Facebook, Patient, Private Securities Litigation Reform Act, COVID-19, University of California, San Francisco, PCOS, Adult, Children's Hospital Los Angeles, Drug, Leadership, Woman, Anovulation, Endocrinology, Growth, Drug development, Industry, CAH, LinkedIn, YouTube, Pharmaceutical industry, Spruce, Allergan

We are pleased to welcome Will as our Chief Medical Officer, and we look forward to his leadership and guidance as we continue to advance our pipeline of treatments for patients with rare endocrine disorders, said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences.

Key Points: 
  • We are pleased to welcome Will as our Chief Medical Officer, and we look forward to his leadership and guidance as we continue to advance our pipeline of treatments for patients with rare endocrine disorders, said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences.
  • He joins Spruce from 89bio, Inc., where he served as Vice President, Clinical Development.
  • "It is a privilege to be joining Spruce at such an important time in the companys growth, said Will Charlton, M.D., M.A.S., Chief Medical Officer of Spruce Biosciences.
  • Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need.

EMD Serono Launches New Sustainable Slim Pack for Fertility Medication

Retrieved on: 
Thursday, February 17, 2022
Carbon, Abdominal pain, Calendar, Stroke, Thrombus, Itchy, Bruise, Cyst, Hospital, Face, Epistasis, Ovarian hyperstimulation syndrome, ART, Anovulation, OHSS, Pregnancy, Merck Serono, Birth, Female, Structured Product Labeling, Neoplasm, Woman, RFF, Research, Pen, FSH, Vitamin, Skin, Life, PCOS, Heart, Diarrhea, CO2, Rash, Headache, Risk, Infection, Use, Brain, Health, Death, Weight gain, Breast, Hypothalamus, Miscarriage, Pain, Vomiting, Carbon footprint, Blood, Thrombosis, Multiple sclerosis, Asthma, Patient, Cancer, Bronchoscopic lung volume reduction (BLVR), Transport, Polycystic ovary syndrome, Efficiency, Infertility, Merck Group, Uterus, FDA, KPMG, Nausea, Multimedia, Stomach, Allergy, Pharmaceutical industry, Recycling, Birth control, Medical imaging, Beekeeping, Merck

ROCKLAND, Mass., Feb. 17, 2022 /PRNewswire/ -- EMD Serono , the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced the launch of its new Slim Pack fertility medication packaging, reduced in size forconvenience and environmental impact.

Key Points: 
  • ROCKLAND, Mass., Feb. 17, 2022 /PRNewswire/ -- EMD Serono , the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced the launch of its new Slim Pack fertility medication packaging, reduced in size forconvenience and environmental impact.
  • "Our new Slim Pack isan initiative we hope will drive convenience while reducing our overall carbon footprint."
  • Slim Pack will lower GONAL-f RFF* Redi-ject's global carbon footprint by 33%.
  • Plastic savings calculated using the unit weight of individual plastic tray and multiplied by the total production volume in one calendar year, once Slim Pack fully implemented across all fertility pens worldwide.

Organon Completes Acquisition of Forendo Pharma

Retrieved on: 
Monday, December 13, 2021
Health, Consumer, Women, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Forward-looking statement, U.S. Securities and Exchange Commission, Security (finance), Lead, Company, Physician, Patent, NYSE, Private Securities Litigation Reform Act, MRK, Industry, Woman, Seed, COVID-19, Acquisition, Research and development, HSD17B1, SEC, Chronic liver disease, Endometriosis, Moelis & Company, Novartis, OGN, Tissue, Achievement, Prevalence, Investment, Anovulation, Intracrine, Form 10-K, HSD17B, PCOS, News, Health, Pharmaceutical industry, Risk management, Merck, Organon, Organon, Forendo, ORGANON, FORENDO

Organon (NYSE: OGN), a global womens healthcare company, today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in womens health.

Key Points: 
  • Organon (NYSE: OGN), a global womens healthcare company, today announced the completion of its acquisition of Forendo Pharma, a clinical-stage drug development company focused on novel treatments in womens health.
  • Here for her health, Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas.
  • These statements include statements about the acquisition of Forendo and the potential for innovation and future treatment options.
  • Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Gynov SAS announces investment from eureKARE SA

Retrieved on: 
Friday, November 26, 2021
GMP, Patient, Anovulation, CEO, Synthetic, Industry, Company, Partnership, Health, Infertility, Synthetic biology, SA, Solution, Microbiota, Endometriosis, Investment, Microbiome, Marketing, Biotechnology, Dietary supplement, Plasma protein binding, United, Food, Pharmaceutical industry

Gynov utilizes robust scientific and medical evidence to select relevant, high quality molecules and has found microbiota modulators to have an increasing role in human health.

Key Points: 
  • Gynov utilizes robust scientific and medical evidence to select relevant, high quality molecules and has found microbiota modulators to have an increasing role in human health.
  • For the development of health products, Gynov employs an approach comparable to that of the pharmaceutical industry.
  • Pierre-Yves Mousset, Chief Executive Officer of Gynov, said: Currently, Gynov markets its products in nearly 30 countries, through agreements with major pharmaceutical groups.
  • eureKARE's investment is a real opportunity to consolidate and accelerate the rapid development of Gynov.